Published in Gastroenterology on August 01, 1997
Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart (2002) 1.89
Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut (1999) 1.00
Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol (2011) 0.99
Clinical use of albumin in hepatology. Blood Transfus (2009) 0.96
Pre- and postoperative systemic hemodynamic evaluation in patients subjected to esophagogastric devascularization plus splenectomy and distal splenorenal shunt: a comparative study in schistomomal portal hypertension. World J Gastroenterol (2007) 0.95
Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol (2012) 0.94
Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol (2013) 0.92
Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol (2013) 0.91
Beta-blockers in liver cirrhosis. Ann Gastroenterol (2014) 0.90
Evaluation and management of patients with refractory ascites. World J Gastroenterol (2009) 0.89
Cirrhotic cardiomyopathy. World J Gastroenterol (2015) 0.84
Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol (2015) 0.82
Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol (2014) 0.82
Albumin reduces paracentesis-induced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and meta-analysis. Biomed Res Int (2013) 0.82
Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res (2010) 0.82
Cardiac function in patients with early cirrhosis during maximal beta-adrenergic drive: a dobutamine stress study. PLoS One (2014) 0.81
Paracentesis-induced circulatory dysfunction: a primer for the interventional radiologist. Semin Intervent Radiol (2014) 0.81
Transjugular intrahepatic portosystemic shunt in the management of refractory ascites. Semin Intervent Radiol (2005) 0.80
Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int (2008) 0.79
Effects of paracentesis on hemodynamic parameters and respiratory function in critically ill patients. BMC Gastroenterol (2014) 0.79
Clinical use of albumin. Blood Transfus (2013) 0.79
The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction. Clin Mol Hepatol (2015) 0.78
Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. Saudi J Gastroenterol (2014) 0.76
Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised. Transfus Med Hemother (2016) 0.76
Hyponatremia in Patients with Cirrhosis of the Liver. J Clin Med (2014) 0.76
Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion. World J Hepatol (2016) 0.76
Management of refractory ascites in cirrhosis: Are we out of date? World J Hepatol (2016) 0.75
The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol (2012) 0.75
Low dose albumin for the prevention of renal impairment following large volume paracentesis in cirrhosis. Pak J Med Sci (2015) 0.75
NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis. ISRN Hepatol (2013) 0.75
What we know about paracentesis induced circulatory dysfunction? Clin Mol Hepatol (2015) 0.75
AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Blood Transfus (2016) 0.75
Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. BMJ Open Gastroenterol (2016) 0.75
Randomized, controlled pilot study comparing large-volume paracentesis using wall suction and traditional glass vacuum bottle methods. Therap Adv Gastroenterol (2014) 0.75
Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist. Gastroenterol Hepatol (N Y) (2006) 0.75
Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf) (2017) 0.75
Prevention of the Paracentesis-Induced Circulatory Dysfunction (PICD) in Cirrhosis: Is the SPA Treatment Worthwhile? Dig Dis Sci (2016) 0.75
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology (2001) 6.88
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet (1995) 6.06
Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med (1999) 5.89
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (1998) 3.62
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology (1993) 3.28
Compensated cirrhosis: natural history and prognostic factors. Hepatology (1987) 3.01
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol (2001) 2.73
Effects of somatostatin on renal function in cirrhosis. Gastroenterology (1992) 2.68
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology (1995) 2.47
Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37
Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology (1990) 2.31
Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology (1994) 2.27
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol (1999) 2.14
Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology (1998) 2.10
Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology (1996) 2.00
Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology (1993) 1.97
Beta-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology (1989) 1.97
Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol (1999) 1.92
Circulating levels of endothelin in cirrhosis. Gastroenterology (1993) 1.91
Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol (2001) 1.89
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology (1998) 1.87
Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet (1989) 1.86
Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol (1986) 1.84
Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology (1998) 1.83
Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology (1993) 1.79
Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology (1988) 1.76
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol (1998) 1.76
Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology (1988) 1.74
Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology (1988) 1.73
Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology (1984) 1.73
Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology (1996) 1.68
Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology (1990) 1.67
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology (1993) 1.67
Fulminant hepatic failure. Lancet (1997) 1.66
In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology (2001) 1.66
Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology (1999) 1.64
Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology (2001) 1.62
Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology (1998) 1.60
Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis (1976) 1.59
Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet (1993) 1.57
Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology (1992) 1.57
Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol (1998) 1.55
Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. Hepatology (1994) 1.54
Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. Am J Gastroenterol (1999) 1.53
Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. J Hepatol (2000) 1.53
Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology (1990) 1.52
Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology (1985) 1.50
Cyclosporine-associated mutism in liver transplant patients. Neurology (1996) 1.49
Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol (1998) 1.49
Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol (1994) 1.49
A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol (2001) 1.49
Endoscopic sclerotherapy in upper gastrointestinal bleeding due to the Mallory-Weiss syndrome. Am J Gastroenterol (1994) 1.48
Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology (1992) 1.45
Limitations of laser-Doppler velocimetry and reflectance spectrophotometry in estimating gastric mucosal blood flow. Am J Physiol (1992) 1.43
Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology (1992) 1.42
Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology (1988) 1.40
Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices. Results in 151 consecutive episodes. Dig Dis Sci (1988) 1.40
Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure. Gastroenterology (1992) 1.40
[Comparative analysis of articles published by Spanish authors (1993-1997) in biomedical journals with high impact factor]. Med Clin (Barc) (2000) 1.39
[Pleural empyema caused by Cryptococcus neoformans in a patient with liver cirrhosis]. Gastroenterol Hepatol (1996) 1.38
[Screening for excessive alcohol consumption]. Med Clin (Barc) (1994) 1.38
[Autoimmune cholangitis or primary biliary cirrhosis without antimitochondrial antibodies?]. Gastroenterol Hepatol (1997) 1.38
Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. Hepatology (1984) 1.36
Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet (1985) 1.36
Feeding S-adenosyl-L-methionine attenuates both ethanol-induced depletion of mitochondrial glutathione and mitochondrial dysfunction in periportal and perivenous rat hepatocytes. Hepatology (1995) 1.35
Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology (1983) 1.33
Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology (1980) 1.33
Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology (1995) 1.31
Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis (2010) 1.31
Biocompatibility aspects of new stent technology. J Am Coll Cardiol (1998) 1.30
Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int (1997) 1.29